NASDAQ · PLUR
Healthcare · Biotechnology
$1.24
Up+$0.04 (+3.33%)
Updated Nov 1, 2026, 5:04 PM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PLUR
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
PLUR closed at $1.24 after 20 trading sessions, up 19.81% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $1.305 | $1.305 | $1.2001 | $1.24 | 29.34K |
| Oct 29, 2026 | $1.255 | $1.34 | $1.18 | $1.20 | 38.53K |
| Oct 28, 2026 | $1.20 | $1.43 | $1.19 | $1.23 | 227.58K |
| Oct 27, 2026 | $1.21 | $1.30 | $1.15 | $1.19 | 132.78K |
| Oct 26, 2026 | $1.18 | $1.3559 | $0.96 | $1.12 | 490.46K |
| Oct 23, 2026 | $1.06 | $1.24 | $0.965 | $0.99 | 70.24K |
| Oct 22, 2026 | $1.06 | $1.07 | $1.01 | $1.01 | 10.43K |
| Oct 21, 2026 | $1.00 | $1.0846 | $0.9078 | $1.05 | 50.98K |
| Oct 20, 2026 | $0.89 | $0.949 | $0.89 | $0.90 | 12.61K |
| Oct 19, 2026 | $0.9028 | $0.9588 | $0.85 | $0.8501 | 8.05K |
| Oct 16, 2026 | $0.99 | $0.99 | $0.9299 | $0.9299 | 9.2K |
| Oct 15, 2026 | $0.93 | $0.9613 | $0.93 | $0.94 | 1.96K |
| Oct 14, 2026 | $0.95 | $0.95 | $0.925 | $0.93 | 4.82K |
| Oct 13, 2026 | $0.9594 | $0.96 | $0.9102 | $0.94 | 14.92K |
| Oct 12, 2026 | $0.91 | $0.98 | $0.8677 | $0.9699 | 7.7K |
| Oct 9, 2026 | $0.9665 | $0.9665 | $0.85 | $0.9532 | 1.45K |
| Oct 8, 2026 | $1.01 | $1.01 | $0.99 | $1.00 | 6.05K |
| Oct 7, 2026 | $0.98 | $1.04 | $0.85 | $1.04 | 61.5K |
| Oct 6, 2026 | $1.05 | $1.0699 | $0.9818 | $0.99 | 6.15K |
| Oct 5, 2026 | $1.01 | $1.0638 | $0.9994 | $1.035 | 6.05K |
The latest Smart Investors Daily articles mentioning PLUR.
Company
Market Activity
Research & News
PLUR research
Company profile and research snapshot.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 2, 2025 | Alliance Global Partners | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Oct 30, 2026
Pluri Inc. (PLUR) Discusses Commercialization Strategy, ZEO ScientifiX Transaction and Financial Flexibility October 29, 2026 8:30 AM EDTCompany...
Yahoo · Oct 27, 2026
English-language call at 8:30 a.m. Eastern Time and Hebrew-language call at 11:00 a.m. Israel Time on Thursday, October 29, 2026HAIFA, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq and TASE: PLUR) (“Pluri” or the “Company”), a biotechnology company advancing cell-based solutions for health and longevity, will host an online investor conference via Zoom this coming Thursday, October 29, 2026, featuring Mr. Yaky Yanay, CEO and President of Pluri and Mr. Alejandro Weinstein, Chairman
Yahoo · Oct 26, 2026
Partnership combines Pluri’s proprietary cell technology and clinical-development experience with ZEO’s biologics manufacturing expertise, established physician network, and sales, marketing, and educational infrastructure Pluri and ZEO Scientifix Strategic Agreement Ian Bothwell, CEO of ZEO, Bob Smoley, Founder of ZEO, Yaky Yanay CEO of Pluri Established U.S. commercial platform: ZEO contributes biologics manufacturing, scientific expertise, an existing product portfolio, physician relationship
Benzinga · Oct 26, 2026
Established U.S. commercial platform: ZEO contributes biologics manufacturing, scientific expertise, an existing product portfolio, physician relationships, and dedicated sales, marketing, and educational
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PLUR.
